BioNTech and Genentech halt Phase 2 trial of personalized mRNA cancer vaccine

BioNTech and its partner Genentech announced the termination of a Phase 2 study evaluating a personalized mRNA cancer vaccine. The decision was made shortly after the trial had entered its second stage.

The move comes just a week after Moderna and Merck reported breakthrough results with their own mRNA‑based cancer approaches, albeit in a different tumor type. Those successes have heightened expectations for the broader mRNA oncology field.

While BioNTech did not provide detailed reasons for the halt, the termination underscores the technical and clinical challenges that still confront personalized cancer vaccine programs. Investors and industry observers will watch how the companies re‑allocate resources and adjust their pipelines moving forward.